Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

The Lancet. Respiratory Medicine
Dongsheng YueChangli Wang

Abstract

Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant erlotinib therapy improves 2-year disease-free survival compared with chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive stage IIIA NSCLC. In this randomised, open-label, phase 2 trial, eligible patients aged 18-75 years who had undergone complete (R0) resection of histologically or pathologically confirmed stage IIIA EGFR mutation-positive NSCLC and had not received any previous anticancer therapies were enrolled. Patients were randomly assigned (1:1) to receive either adjuvant erlotinib (150 mg once daily administered orally) or vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m2 intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m2 intravenously on day 1 of each 21-day cycle]). Randomisation was done by Simon's minimisation with a random element and was stratified by EGFR activating mutation type (exon 19 vs 21), histology (adenocarcinoma vs non-adenocarcinoma), and smoking status (smoker vs non-smoker). The primary endpoint in the unblinded intention-to-treat analysis was 2-year disease-free surv...Continue Reading

Citations

Mar 27, 2020·Japanese Journal of Clinical Oncology·Takuma TsukiokaNoritoshi Nishiyama
Sep 22, 2020·The New England Journal of Medicine·Yi-Long WuUNKNOWN ADAURA Investigators
Jul 1, 2020·Dalton Transactions : an International Journal of Inorganic Chemistry·Ruihao LiYun Lin
Jun 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Zhao ZhongYi-Long Wu
Oct 1, 2020·Pharmaceuticals·Connor O'LearyKen J O'Byrne
Sep 4, 2020·International Journal of Molecular Sciences·Alex FriedlaenderChristian D Rolfo
Oct 29, 2020·The New England Journal of Medicine·David Planchard
Oct 31, 2020·Current Opinion in Oncology·Lingyun YeFei Zhou
Dec 18, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Zhao ZhongYi-Long Wu
Nov 13, 2020·The Oncologist·Erin L SchenkPaul A Bunn
Dec 15, 2020·The Oncologist·Alfredo AddeoAlex Friedlaender
Dec 11, 2020·The Oncologist·Michael J Jelinek, Charu Aggarwal
Jan 9, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Saiama N Waqar, Ramaswamy Govindan
Jan 7, 2021·Revue des maladies respiratoires·M Coureau, T Berghmans
Nov 14, 2020·Current Opinion in Oncology·Tetsuya Mitsudomi, Junichi Soh
Feb 18, 2021·The New England Journal of Medicine·Roy S HerbstMasahiro Tsuboi
Oct 29, 2020·Journal of Hematology & Oncology·Liling HuangYuankai Shi
Feb 18, 2021·Expert Opinion on Pharmacotherapy·Luigi CerboneCarlo Genova
Nov 17, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Wan Ling TanFan Yang
Mar 2, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jordi Remon, Lizza E L Hendriks
Mar 11, 2021·Global Health & Medicine·Hiroshi TakumidaGo Naka
Mar 12, 2021·The Journal of Thoracic and Cardiovascular Surgery·David R JonesRoy S Herbst
May 1, 2021·Current Opinion in Pulmonary Medicine·Francesco Passiglia, Giorgio V Scagliotti
Jun 11, 2021·JCO Precision Oncology·Amit A KulkarniRodrigo Dienstmann
May 19, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne-Marie C DingemansChandra P Belani
Jul 31, 2021·The Lancet Regional Health. Western Pacific·Qiaofeng ZhongYuankai Shi
Sep 17, 2021·Expert Review of Anticancer Therapy·Carolina GabayChristian Rolfo Cervetto
Nov 3, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hirohito TadaUNKNOWN West Japan Oncology Group
Nov 19, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Si-Yang LiuYi-Long Wu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.